Topical pharmaceutical composition comprising nanonized silver sulfadiazine
The invention relates to a topical pharmaceutical composition for burn treatment and microbial infections on human beings or animals. The pharmaceutical composition comprises 0.1% w/w to 1.0% w/w of an antimicrobial drug, i.e., silver sulfadiazine and 0.2% w/w antiseptic, i.e., chlorhexidine gluconate, wherein silver sulfadiazine is in nanonized form.
1. A dose-reduced topical pharmaceutical composition consisting of 0.5% w/w of nanonized silver sulfadiazine and 0.2% w/w chlorhexidine gluconate, and one or more pharmaceutically acceptable excipients selected from the group consisting of thickening agents, emulsifying agents, preservatives, chelating agents, pH modifiers, coloring agents, perfumes, and antioxidants, wherein the topical pharmaceutical composition exhibits a similar efficacy when compared to a marketed composition containing 1.0% w/w micronized silver sulfadiazine.
2. The topical pharmaceutical composition of claim 1 , wherein the efficacy is determined by:
a) proportion of patients achieving complete wound closure by day 21 of the treatment period; or
b) microbial log reduction of Pseudomonas aeruginosa count in thermal injury model in rats.
3. The topical pharmaceutical composition of claim 2 , wherein the application of the nanonized composition to patients leads to complete wound closure by day 21 of treatment period in at least 90% of the total patient population.
4. The topical pharmaceutical composition of claim 2 , wherein the microbial log reduction of Pseudomonas aeruginosa count in a thermal injury model in rats using the topical pharmaceutical composition is comparable to that caused by the composition containing 1.0% w/w micronized silver sulfadiazine.
5. The topical pharmaceutical composition of claim 1 , wherein the thickening agent is selected from one or more of soft paraffin, aluminum stearate, cetostearyl alcohol, propylene glycol, polyethylene glycols, povidone, wool-fat, hydrogenated lanolin, or beeswax.
6. The topical pharmaceutical composition of claim 1 , wherein the emulsifying agent is selected from one or more of cetomacrogol, non-ethoxylated glyceryl monostearate, carbopols, cetearyl alcohol, sodium stearoyl lactylate, or lecithin.
7. The topical pharmaceutical composition of claim 1 , wherein the chelating agent is selected from one or more of dimercaprol, ethylene diamine tetra acetic acid (EDTA), ethylene glycol tetraacetic acid, deferoxamine, or alfa lipoic acid.
8. The topical pharmaceutical composition of claim 1 , wherein the pH modifier is selected from one or more of citric acid, sodium citrate, acetic acid, sodium acetate, phosphoric acid, sodium phosphate, borax, or sodium hydroxide.
9. The topical pharmaceutical composition according to claim 1 , wherein the composition is in the form of a cream, lotion, ointment, or gel.
10. The topical pharmaceutical composition of claim 1 , wherein the nanonized silver sulfadiazine and chlorhexidine gluconate are the sole active therapeutic agents in the composition.
11. A dose-reduced topical pharmaceutical composition comprising of 0.5% w/w of nanonized silver sulfadiazine and one or more pharmaceutically acceptable excipients selected from the group consisting of thickening agents, emulsifying agents, preservatives, chelating agents, pH modifiers, coloring agents, perfumes, and antioxidants, wherein the topical pharmaceutical composition exhibits a similar efficacy when compared to a marketed composition containing 1.0% w/w micronized silver sulfadiazine.